更正：埃尔斯沃思，M.；奥斯特罗斯基-采希纳，L. 艾沙康唑：作用机制、临床疗效及耐药性。2020年，，324。
Correction: Ellsworth, M.; Ostrosky-Zeichner, L. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. 2020, , 324.
作者信息
Ellsworth Misti, Ostrosky-Zeichner Luis
机构信息
Division of Pediatric Infectious Diseases, UT Health McGovern Medical School, Houston, TX 77030, USA.
Division of Infectious Diseases, UT Health McGovern Medical School, Houston, TX 77030, USA.
出版信息
J Fungi (Basel). 2025 Mar 17;11(3):226. doi: 10.3390/jof11030226.
Abstract
In the original article [...].
摘要
在原文中 [...]。
相似文献
1
Correction: Ellsworth, M.; Ostrosky-Zeichner, L. Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance. 2020, , 324.更正：埃尔斯沃思，M.；奥斯特罗斯基-采希纳，L. 艾沙康唑：作用机制、临床疗效及耐药性。2020年，，324。
J Fungi (Basel). 2025 Mar 17;11(3):226. doi: 10.3390/jof11030226.
2
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.艾沙康唑：作用机制、临床疗效及耐药性
J Fungi (Basel). 2020 Nov 29;6(4):324. doi: 10.3390/jof6040324.
3
In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan.日本 140 株参考真菌株和 165 株临床分离酵母菌的体外异康唑活性。
Int J Antimicrob Agents. 2010 Oct;36(4):324-31. doi: 10.1016/j.ijantimicag.2010.06.003. Epub 2010 Jul 31.
4
Isavuconazole, micafungin, and 8 comparator antifungal agents' susceptibility profiles for common and uncommon opportunistic fungi collected in 2013: temporal analysis of antifungal drug resistance using CLSI species-specific clinical breakpoints and proposed epidemiological cutoff values.2013年收集的常见和罕见机会性真菌对艾沙康唑、米卡芬净及8种对照抗真菌药物的敏感性概况：使用临床和实验室标准协会（CLSI）特定菌种临床断点及建议的流行病学截断值对抗真菌药物耐药性进行的时间分析
Diagn Microbiol Infect Dis. 2015 Aug;82(4):303-13. doi: 10.1016/j.diagmicrobio.2015.04.008. Epub 2015 Apr 29.
5
Isavuconazole: a new extended spectrum triazole for invasive mold diseases.艾沙康唑：一种用于侵袭性霉菌病的新型广谱三唑类药物。
Future Microbiol. 2015;10(5):693-708. doi: 10.2217/fmb.15.34. Epub 2015 May 21.
6
Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections.艾沙康唑概况及其在治疗严重侵袭性真菌感染中的潜力。
Infect Drug Resist. 2013 Oct 22;6:163-74. doi: 10.2147/IDR.S51340.
7
Isavuconazole for the Treatment of Invasive Mold Disease in Solid Organ Transplant Recipients: A Multicenter Study on Efficacy and Safety in Real-life Clinical Practice.艾沙康唑治疗实体器官移植受者侵袭性霉菌病：真实临床实践中疗效与安全性的多中心研究
Transplantation. 2023 Mar 1;107(3):762-773. doi: 10.1097/TP.0000000000004312. Epub 2022 Oct 20.
8
Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators.EUCAST 折点修订：对当代丹麦霉菌分离株对伊曲康唑和对照药物敏感性的影响。
J Antimicrob Chemother. 2020 Sep 1;75(9):2573-2581. doi: 10.1093/jac/dkaa212.
9
Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.伊曲康唑治疗侵袭性曲霉病和其他丝状真菌患者的暴露-反应关系。
Antimicrob Agents Chemother. 2017 Nov 22;61(12). doi: 10.1128/AAC.01034-17. Print 2017 Dec.
10
Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis.伊曲康唑治疗毛霉病：一项单臂开放标签试验和病例对照分析。
Lancet Infect Dis. 2016 Jul;16(7):828-837. doi: 10.1016/S1473-3099(16)00071-2. Epub 2016 Mar 9.
本文引用的文献
1
Isavuconazole: Mechanism of Action, Clinical Efficacy, and Resistance.艾沙康唑：作用机制、临床疗效及耐药性
J Fungi (Basel). 2020 Nov 29;6(4):324. doi: 10.3390/jof6040324.
Zotero 插件